Repositioning Candidate Details
| Candidate ID: | R0181 |
| Source ID: | DB00635 |
| Source Type: | approved; vet_approved |
| Compound Type: | small molecule |
| Compound Name: | Prednisone |
| Synonyms: | |
| Molecular Formula: | C21H26O5 |
| SMILES: | [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |
| Structure: |
|
| DrugBank Description: | A synthetic anti-inflammatory glucocorticoid derived from [cortisone].[A187463] It is biologically inert and converted to [prednisolone] in the liver.[L10502] Prednisone was granted FDA approval on 21 February 1955.[L10496] |
| CAS Number: | 53-03-2 |
| Molecular Weight: | 358.4281 |
| DrugBank Indication: | Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.[L10502] |
| DrugBank Pharmacology: | Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Prednisone has a short duration of action as the half life is 2-3 hours.[L10502] Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463] |
| DrugBank MoA: | Prednisone is first metabolized in the liver to its active form, prednisolone, a glucocorticoid agonist corticosteroid.[L10502] The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463] Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463] Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463] |
| Targets: | Glucocorticoid receptor |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |